Early-Onset Colorectal Cancer Patients Too Young for Screening
Part of paid clinical trials in Dallas, Texas.
- Sponsor
- Methodist Health System
- Study ID
- NCT07559825
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 35 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Colorectal cancer — OTHERCRC is a disease that is often associated with older adults (\<50 years). CRC remains the second most common cause of cancer death in males and the third most common cancer death in women. Despite this, CRC incidence has steadily declined in older adults; however, there is a concerning rise of incidence of colorectal cancer in young patients. The incidence of CRC in men and women under the age of 50 steadily increased 2.1 percent per year from 1992 through 2012.
Study Details
This is a population-based retrospective study using the Surveillance, Epidemiology, and End Results (SEER) registry and National Cancer Data Base (NCDB) to look at colorectal cancer (CRC) patients younger than 35 and comparing them against CRC patients older than 35 years of age.
Key Dates
- Start date
- Jan 31, 2020
- Status verified
- Jan 2026
- Primary completion
- Jan 31, 2027
- Completion
- Jan 31, 2028
Study Design
- Enrollment
- 100 participants (estimated)
Arms
- Arm: colorectal cancer (CRC) patients younger than 35The hypothesis is that patients younger than 35 years of age with CRC will present with more advanced disease at diagnosis but will have longer survival overall through more aggressive therapy.
Primary Outcome Measure
Age [ Time Frame: 20 years ]
Central Contacts
- Crystee Cooper, DHEd214-947-1280
- Kavya Mankulangara214-947-4604
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Methodist Dallas Medical Center- Clinical Research Institute | Dallas | Texas | 75203 |
Find similar trials in Dallas, TX
By condition
By specialty
Related Studies
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsPHASE1/PHASE2 · Recruiting · IDEAYA Biosciences · Los Angeles, California
- Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsPHASE1 · Recruiting · Bicara Therapeutics · La Jolla, California